AstraZeneca PLC

LSE:AZN 주식 리포트

시가총액: UK£222.8b

AstraZeneca 향후 성장

Future 기준 점검 4/6

AstraZeneca (는) 각각 연간 13.4% 및 6.2% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 14.1% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 28.9% 로 예상됩니다.

핵심 정보

13.4%

이익 성장률

14.05%

EPS 성장률

Pharmaceuticals 이익 성장10.1%
매출 성장률6.2%
향후 자기자본이익률28.93%
애널리스트 커버리지

Good

마지막 업데이트07 Jul 2026

최근 향후 성장 업데이트

Recent updates

내러티브 업데이트 • Jul 02

AZN: Oncology Approvals And Pipeline Execution Will Support Multi Year Re Rating

Analysts have lifted their AstraZeneca price targets by about £10, citing updated assumptions that include a modestly lower fair value estimate, a slightly higher discount rate, and adjusted expectations for revenue growth, profit margins, and future P/E multiples. Analyst Commentary Recent Street research on AstraZeneca points to a mix of product specific updates and valuation work, with several bullish analysts adjusting their views as new information filters through on the pipeline and regulatory outcomes.
분석 기사 • Jun 19

AstraZeneca (LSE:AZN) Stock Could Be 20.2% Below Fair Value After Recent Pullback

AstraZeneca (LSE:AZN) is back in focus after recent share price pressure, with the stock down about 5% over the past month and past 3 months. This has prompted investors to reassess its long term profile. See our latest analysis for AstraZeneca. Despite the recent share price decline, with the stock down 5.3% on a 90 day share price return basis and currently trading at £131.54, AstraZeneca still shows a 73.7% total shareholder return over five years. This suggests long term holders have seen...
내러티브 업데이트 • Jun 18

AZN: New Approvals And AI Use Will Support Future Repricing

The latest narrative update on AstraZeneca reflects a modest trimming of the analyst fair value estimate to £164.85, as analysts factor in updated revenue growth and profit margin assumptions following recent price target increases and ongoing commentary around the company’s drug pipeline and regulatory outcomes. Analyst Commentary Recent Street research around AstraZeneca centers on how regulators and pricing decisions may affect the company’s growth options, as well as how advisory outcomes could influence execution risk in parts of its pipeline.
내러티브 업데이트 • Jun 03

AZN: Recent Drug Approvals And Key Readouts Will Support Bullish Repricing

Analysts have lifted their AstraZeneca price targets by up to £1,000 per share, pointing to updated valuation work that reflects Baxfendy's FDA approval, recent price target revisions from several banks, and slight tweaks to fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Recent research around AstraZeneca clusters into two camps, with some analysts leaning more optimistic after Baxfendy's approval and a series of price target moves, while others highlight execution and regulatory questions that could affect how those targets are met.
내러티브 업데이트 • Apr 29

AZN: Pipeline Readouts And 2H26 Catalyst Path Will Drive Bullish Repricing

AstraZeneca's analyst price targets have been raised in recent research, with moves such as Guggenheim's lift to £160.00 and Citi's and Morgan Stanley's increases in their London based targets, as analysts point to refreshed models, updated earnings views and a more constructive stance on the pipeline. Analyst Commentary Recent research around AstraZeneca centres on refreshed valuation work, updated earnings paths and how the pipeline feeds into longer term growth expectations.
내러티브 업데이트 • Apr 15

AZN: Updated Oncology Pipeline Outlook Will Support Multi Year Re Rating

Analysts have lifted their AstraZeneca price targets, with several recent moves in the £500 to £1,000 range. They cite stronger confidence in the earnings outlook and pipeline after updated models and conference follow ups.
내러티브 업데이트 • Apr 01

AZN: 1H26 Trial Cluster Will Test Sustained Premium Earnings Expectations

AstraZeneca's updated analyst price target reflects a modest uplift, with the fair value estimate moving from £117.29 to £124.85 as analysts factor in refreshed models after recent results, a higher assumed future P/E of about 25x, and ongoing optimism around the earnings pipeline highlighted in recent research. Analyst Commentary Recent research on AstraZeneca has included a series of price target revisions, with several large banks updating their models following full year results and subsequent investor events.
내러티브 업데이트 • Mar 18

AZN: Oncology Pipeline And Breast Cancer Trial Readouts Will Support Re Rating

Analysts have lifted AstraZeneca's fair value estimate from £182.81 to £205.97 and raised several price targets, citing updated models, a higher assumed profit margin and a more constructive view on the earnings pipeline. Analyst Commentary Recent Street research points to a cluster of upbeat views on AstraZeneca, with several bullish analysts revisiting their models and adjusting price targets after fresh company updates and sector readthroughs.
내러티브 업데이트 • Mar 03

AZN: Oncology Pipeline And 2H26 Catalysts Will Shape Balanced Long-Term Outlook

The updated analyst price target for AstraZeneca increases to £162.67 from £152.79. This reflects broader Street research that highlights stronger earnings potential and a more constructive view on the company’s pipeline and long term growth drivers.
내러티브 업데이트 • Feb 17

AZN: Elevated Margin Assumptions Will Face Pressure From Pipeline And Competition Risks

Narrative Update: AstraZeneca Analyst Price Target Shift Analysts have raised their fair value estimate for AstraZeneca from £108.53 to £117.29, citing updated assumptions for revenue growth, profit margins and a lower future P/E multiple, supported by recent price target increases and fresh bullish coverage across several banks. Analyst Commentary Recent Street research on AstraZeneca has leaned positive, with several banks adjusting fair value estimates and starting coverage with supportive views.
내러티브 업데이트 • Feb 03

AZN: Oncology Pipeline And Manufacturing Investments Will Shape Balanced Long-Term Outlook

Analysts have lifted their AstraZeneca fair value estimate to £152.79 from £150.26, reflecting higher price targets from several firms and updated views on the company’s revenue growth, profit margins and future P/E assumptions. Analyst Commentary Recent Street research on AstraZeneca has been active, with several bullish analysts lifting price targets and initiating positive coverage.
내러티브 업데이트 • Jan 20

AZN: Oncology Pipeline And 2030 Sales Ambition Will Support Re Rating

Narrative Update The analyst price target for AstraZeneca has been nudged higher to reflect a fair value estimate of £182.81 per share, with analysts pointing to supportive Street research that includes recent target upgrades from Deutsche Bank and Barclays, as well as constructive commentary on oncology and the broader biopharma pipeline. Analyst Commentary Recent Street research reflects a cluster of bullish analysts lifting price targets on AstraZeneca, with several pointing to oncology and the broader biopharma pipeline as key parts of their constructive view.
내러티브 업데이트 • Jan 06

AZN: Oncology And Biopharma Execution Will Offset Patent Pressure Concerns

AstraZeneca's implied fair value has shifted from £173.72 to £182.32 as analysts weigh stronger confidence in oncology and broader biopharma sales potential against concerns about approaching patent pressures and a less certain pipeline in breast cancer. Analyst Commentary Recent research shows a split in views, but bullish analysts see room for AstraZeneca's valuation to reflect stronger confidence in oncology and biopharma execution, even as others flag upcoming patent risks and breast cancer pipeline uncertainty.
내러티브 업데이트 • Dec 14

AZN: Oncology Execution And US Manufacturing Expansion Will Drive Long-Term Upside Potential

Analysts have nudged their fair value estimate for AstraZeneca higher to approximately $150.26 from about $146.44, reflecting confidence that the company can deliver on its long term, oncology driven growth ambitions despite mixed views on patent risk and pipeline momentum. Analyst Commentary Recent Street research highlights a sharp divergence in views on AstraZeneca, with some bullish analysts emphasizing the durability of its oncology growth engine and others warning that the valuation already discounts too optimistic a pipeline and patent outcome.
내러티브 업데이트 • Nov 28

AZN: Oncology Pipeline Execution And Patent Expiry Risks Will Define Long-Term Prospects

AstraZeneca's analyst price target was revised slightly higher from £145.43 to £146.44, as analysts cite optimism around the company's oncology franchises and biopharma pipeline. Some remain cautious given upcoming patent pressures and mixed views on pipeline outlook.
내러티브 업데이트 • Nov 14

AZN: Oncology Pipeline Momentum And Patent Pressures Will Shape Outlook Amid Policy Changes

AstraZeneca's analyst price target has inched higher from $144.38 to $145.43, as analysts cite ongoing strength in its oncology franchises and biopharma pipeline, along with improved margin expectations. Analyst Commentary Recent Street research on AstraZeneca reflects a wide range of perspectives on the company's outlook, with both bullish and bearish analysts voicing key points of emphasis around valuation, pipeline potential, and execution risks.
분석 기사 • Nov 13

AstraZeneca's (LON:AZN) Performance Is Even Better Than Its Earnings Suggest

AstraZeneca PLC's ( LON:AZN ) strong earnings report was rewarded with a positive stock price move. We have done some...
내러티브 업데이트 • Oct 31

AZN: In-Market Oncology And U.S. Drug Pricing Will Shape Long-Term Performance

AstraZeneca's analyst-derived fair value has been raised to $144.38 per share from $140.96. This reflects modest increases in pipeline confidence and anticipated revenue growth, as noted by analysts in recent research updates.
내러티브 업데이트 • Oct 17

Breakthrough Pipeline Therapies And Emerging Markets Will Create Lasting Success

AstraZeneca's analyst price target has been raised from £138.16 to £140.96. This reflects a modest increase as analysts highlight both expanding potential for key pipeline products and a tempered outlook on patent risk and competitive pressures in certain therapeutic areas.

이익 및 매출 성장 예측

LSE:AZN - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수
12/31/202871,31516,03914,72221,09620
12/31/202766,85113,96113,25419,14324
12/31/202663,19412,45210,04516,83324
3/31/202660,43910,3897,91914,221N/A
12/31/202558,73910,2258,80614,575N/A
9/30/202558,1279,3999,67915,140N/A
6/30/202556,5018,2958,32713,389N/A
3/31/202554,9827,7729,19513,088N/A
12/31/202454,0737,0357,39811,861N/A
9/30/202451,2066,4956,86711,334N/A
6/30/202449,1336,4407,04511,065N/A
3/31/202447,6116,3315,8879,698N/A
12/31/202345,8115,9556,85810,345N/A
9/30/202344,9945,8967,27010,363N/A
6/30/202344,4856,1636,85410,179N/A
3/31/202343,8404,7056,3579,709N/A
12/31/202244,3513,2887,6849,808N/A
9/30/202245,1552,0406,5388,828N/A
6/30/202244,038-1,2535,7897,617N/A
3/31/202241,487-1,0635,7217,261N/A
12/31/202137,4171124,3505,963N/A
9/30/202132,8161,4715,1846,343N/A
6/30/202129,5283,7715,4216,446N/A
3/31/202127,5833,9774,8996,594N/A
12/31/202026,6173,1963,1444,799N/A
9/30/202025,8712,4973,2734,376N/A
6/30/202025,6992,1483,0573,657N/A
3/31/202025,2471,5222,7893,495N/A
12/31/201924,3841,335N/A2,969N/A
9/30/201924,1372,056N/A3,818N/A
6/30/201923,0712,188N/A3,184N/A
3/31/201922,4032,408N/A2,371N/A
12/31/201822,0902,155N/A2,618N/A
9/30/201821,4502,422N/A1,391N/A
6/30/201822,3422,677N/A3,165N/A
3/31/201822,2382,804N/A3,350N/A
12/31/201722,4653,001N/A3,578N/A
9/30/201722,2733,542N/A4,541N/A
6/30/201721,7403,870N/A3,109N/A
3/31/201722,2923,390N/A3,040N/A
12/31/201623,0023,499N/A4,145N/A
9/30/201623,8162,465N/A2,756N/A
6/30/201624,0622,221N/A3,690N/A
3/31/201624,7662,921N/A4,589N/A
12/31/201524,7082,825N/A3,324N/A
9/30/201525,0251,696N/A4,595N/A

애널리스트 향후 성장 전망

수입 대 저축률: AZN 의 연간 예상 수익 증가율(13.4%)이 saving rate(3.4%)보다 높습니다.

수익 vs 시장: AZN 의 연간 수익(13.4%)이 UK 시장(11.4%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 수익: AZN 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: AZN 의 수익(연간 6.2%)이 UK 시장(연간 4.7%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 매출: AZN 의 수익(연간 6.2%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: AZN의 자본 수익률은 3년 후 28.9%로 높을 것으로 예상됩니다.

성장 기업 찾아보기

7D

1Y

7D

1Y

7D

1Y

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/07/07 04:14
종가2026/07/07 00:00
수익2026/03/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

AstraZeneca PLC는 56명의 분석가가 다루고 있습니다. 이 중 24명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
null nullABG Sundal Collier
John EadeArgus Research Company
Odile RundquistBaader Helvea Equity Research